Clinical trial NCT00000490 - References

Cardiovascular Diseases — Program on Surgical Control of Hyperlipidemias (POSCH)

Citation(s)

•   Bissett JK, Matts J, Sharma B
  Residual myocardial jeopardy in patients with Q-wave and non-Q-wave infarctions. Br Heart J. 1987 Nov;58(5):460-4.
•   Bissett JK, Ngo WL, Wyeth RP, Matts JP
  Angiographic progression to total coronary occlusion in hyperlipidemic patients after acute myocardial infarction. POSCH Group. Am J Cardiol. 1990 Dec 1;66(19):1293-7.
•   Bissett JK, Wyeth RP, Matts JP, Johnson JW
  Plasma lipid concentrations and subsequent coronary occlusion after a first myocardial infarction. The POSCH Group. Am J Med Sci. 1993 Mar;305(3):139-44.
•   Buchwald H, Boen JR, Nguyen PA, Williams SE, Matts JP
  Plasma lipids and cardiovascular risk: a POSCH report. Program on the Surgical Control of the Hyperlipidemias. Atherosclerosis. 2001 Jan;154(1):221-7.
•   Buchwald H, Bourdages HR, Campos CT, Nguyen P, Williams SE, Boen JR
  Impact of cholesterol reduction on peripheral arterial disease in the Program on the Surgical Control of the Hyperlipidemias (POSCH). Surgery. 1996 Oct;120(4):672-9.
•   Buchwald H, Campos CT, and the POSCH Group: Preliminary Results of the Program on the Surgical Control of the Hyperlipidemias (POSCH)
  Chapter in: Proceedings of the 7th International Atherosclerosis and Cardiovascular Disease Meeting. Dordrecht: Kluwer Academic Publishers, in press, 1990.
•   Buchwald H, Campos CT, Boen JR, Nguyen P, Williams SE, Lau J, Chalmers TC
  Gender-based mortality follow-up from the Program on the Surgical Control of the Hyperlipidemias (POSCH) and meta-analysis of lipid intervention trials. Women in POSCH and other lipid trials. Ann Surg. 1996 Oct;224(4):486-98; discussion 498-500.
•   Buchwald H, Campos CT, Boen JR, Nguyen PA, Williams SE
  Disease-free intervals after partial ileal bypass in patients with coronary heart disease and hypercholesterolemia: report from the Program on the Surgical Control of the Hyperlipidemias (POSCH). J Am Coll Cardiol. 1995 Aug;26(2):351-7.
•   Buchwald H, Campos CT, Matts JP, Fitch LL, Long JM, Varco RL
  Women in the POSCH trial. Effects of aggressive cholesterol modification in women with coronary heart disease. The POSCH Group. Program on the Surgical Control of the Hyperlipidemias. Ann Surg. 1992 Oct;216(4):389-98; discussion 398-400.
•   Buchwald H, Campos CT
  Control of risk factors in atherosclerosis. POSCH Report. Ann N Y Acad Sci. 1995 Jan 17;748:342-55; discussion 355-6.
•   Buchwald H, Campos CT
  Partial ileal bypass in the therapy of familial hypercholesterolemia. The POSCH Group. Beitr Infusionsther. 1988;23:47-60. Review.
•   Buchwald H, Campos CT: Partial Ileal Bypass for Control of Hyperlipidemia and Atherosclerosis
  Chapter in: Gibbon's Surgery of the Chest, Fifth Edition; Sabiston DC Jr., Spencer FC (Eds); W.B. Saunders Company, Philadelphia, PA, pp 1799-1820, 1990.
•   Buchwald H, Fitch L, Moore RB
  Overview of randomized clinical trials of lipid intervention for atherosclerotic cardiovascular disease. Control Clin Trials. 1982 Sep;3(3):271-83.
•   Buchwald H, Fitch L, Varco RL
  Ileal bypass for hyperlipidemia. World J Surg. 1985 Dec;9(6):850-9.
•   Buchwald H, Fitch L, Varco RL
  Surgical intervention in atherosclerosis: partial ileal bypass and the Program on Surgical Control of the Hyperlipidemias (POSCH). Pharmacol Ther. 1985;29(1):93-109. Review.
•   Buchwald H, Fitch L, Varco RL: Partial Ileal Bypass; Hypercholesterolemia; Atherosclerosis
  In Nyhus LM, Nelson RL (Eds.): Blackwell Scientific Publ Inc, Boston, MA, 1985, in press.
•   Buchwald H, Fitch LL, Matts JP, Johnson JW, Hansen BJ, Stuenkel MR, Brooks HB
  Perception of quality of life before and after disclosure of trial results: a report from the Program on the Surgical Control of the Hyperlipidemias (POSCH). Control Clin Trials. 1993 Dec;14(6):500-10.
•   Buchwald H, Hunter DW, Tuna N, Williams SE, Boen JR, Hansen BJ, Titus JL, Campos CT
  Myocardial infarction and percent arteriographic stenosis of culprit lesion: report from the Program on the Surgical Control of the Hyperlipidemias (POSCH). Atherosclerosis. 1998 Jun;138(2):391-401.
•   Buchwald H, Matts JP, Fitch LL, Campos CT, Sanmarco ME, Amplatz K, Castaneda-Zuniga WR, Hunter DW, Pearce MB, Bissett JK, et al
  Changes in sequential coronary arteriograms and subsequent coronary events. Surgical Control of the Hyperlipidemias (POSCH) Group. JAMA. 1992 Sep 16;268(11):1429-33.
•   Buchwald H, Matts JP, Fitch LL, Varco RL, Campbell GS, Pearce M, Yellin A, Smink RD Jr, Sawin HS Jr, Campos CT, et al
  Program on the Surgical Control of the Hyperlipidemias (POSCH): design and methodology. POSCH Group. J Clin Epidemiol. 1989;42(12):1111-27.
•   Buchwald H, Matts JP, Hansen BJ, Long JM, Fitch LL
  Program on Surgical Control of the Hyperlipidemias (POSCH): recruitment experience. Control Clin Trials. 1987 Dec;8(4 Suppl):94S-104S.
•   Buchwald H, Moore RB, Matts JP, Long JM, Varco RL, Campbell GS, Pearce MB, Yellin AE, Blankenhorn DH, Holmes WL, Smink RD Jr, Sawin HS Jr
  The Program on the Surgical Control of the Hyperlipidemias: a status report. Surgery. 1982 Oct;92(4):654-62.
•   Buchwald H, Moore RB, Rucker RD Jr, Amplatz K, Castaneda WR, Francoz RA, Pasternak RC, Varco RL
  Clinical angiographic regression of atherosclerosis after partial ileal bypass. Atherosclerosis. 1983 Jan;46(1):117-28.
•   Buchwald H, Moore RB, Varco RL
  Maximum lipid reduction by partial ileal bypass: a test of the lipid-atherosclerosis hypothesis. Lipids. 1977 Jan;12(1):53-8.
•   Buchwald H, Moore RB, Varco, RL: Surgery in the Therapy of Atherosclerosis: Partial Ileal Bypass
  In Atherosclerosis: Clinical Evaluation and Therapy. MTP Press Limited, International Medical Publication, 1982.
•   Buchwald H, Rucker RD Jr
  , Moore RB, et al: Regression of Atherosclerosis by Surgical Cholesterol Reduction. In Noseda G et al (Eds): Lipoproteins and Coronary Atherosclerosis. Elsevier Biomedical Press, 417, 1982.
•   Buchwald H, Varco RL, Boen JR, Williams SE, Hansen BJ, Campos CT, Campbell GS, Pearce MB, Yellin AE, Edmiston WA, Smink RD Jr, Sawin HS Jr
  Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: five-year posttrial follow-up report from the POSCH. Program on the Surgical Control of the Hyperlipidemias. Arch Intern Med. 1998 Jun 8;158(11):1253-61.
•   Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, Pearce MB, Yellin AE, Edmiston WA, Smink RD Jr, et al
  Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med. 1990 Oct 4;323(14):946-55.
•   Buchwald H: Intestinal Bypass for Hypercholesterolemia
  In Nyhus LM (Ed.). Mastery of Surgery. Little Brown and Co., Vol II, 901-907, 1984.
•   Buchwald H: Partial Ileal Bypass: A Surgical Approach to Cholesterol Lowering
  In Perspectives in Lipid Disorders. McGraw-Hill Pub. Co., New York, Vol. 3, 1985.
•   Campos CT, Buchwald H, and the POSCH Group: The Program on the Surgical Control of the Hyperlipidemias (POSCH): Demonstration of the Beneficial Effects of Treatment of Hypercholesterolemia
  Cardiovasc Risk Factors, 2:261-275, 1992.
•   Campos CT, Matts JP, Fitch LL, et al: Modification of Plasma Lipoproteins Following Partial Ileal Bypass
  Five-Year Results of the Program of the Surgical Control of the Hyperlipidemias. In: Atherosclerosis VIII, Proceedings of the 8th International Symposium on Atherosclerosis, Rome, 9-13, October 1988; G. Crepaldi et al, (Eds), Elsevier Science Publishers B.V., Amsterdam, pp 769-774, 1989.
•   Campos CT, Matts JP, Fitch LL, Speech JC, Long JM, Buchwald H
  Lipid results of partial ileal bypass in patients with heterozygous, type II-A hyperlipoproteinemia. Program on the Surgical Control of the Hyperlipidemias. Surgery. 1990 Oct;108(4):601-10; discussion 610-1.
•   Campos CT, Matts JP, Fitch LL, Speech JC, Long JM, Buchwald H
  Lipoprotein modification achieved by partial ileal bypass: five-year results of The Program on the Surgical Control of the Hyperlipidemias. Surgery. 1987 Aug;102(2):424-32.
•   Campos CT, Matts JP, Fitch LL, Speech JC, Long JM, Buchwald H
  Normalization of lipoproteins following partial ileal bypass in individual WHO lipoprotein phenotypes. Curr Surg. 1988 Sep-Oct;45(5):380-2. Review.
•   Campos CT, Matts JP, Santilli SM, Fitch LL, Long JM, Speech JC, Buchwald H
  Predictors of total and low-density lipoprotein cholesterol change after partial ileal bypass. Am J Surg. 1988 Jan;155(1):138-46.
•   Fitch LL, Buchwald H, Matts JP, Johnson JW, Campos CT, Long JM
  Effect of aspirin use on death and recurrent myocardial infarction in current and former cigarette smokers. Program on the Surgical Control of the Hyperlipidemias Group. Am Heart J. 1995 Apr;129(4):656-62.
•   Gould AL, Cariski AT
  Meta-analysis by the Program on the Surgical Control of the Hyperlipidemias (POSCH) investigators. Ann Surg. 1998 Feb;227(2):314-6.
•   Irani EA, Matts JP, Long JM, Slagle JR, and the POSCH Group: Using Artificial Neural Nets for Statistical Discovery: Observations After Using Back-Propagation, Expert Systems, and Multiple Linear Regression on Clinical Trial Data
  Complex Systems, 3:295-311, 1989.
•   Jelovsek FR, Bolinger RE, Davis RE, et al: Guidelines for User Access to Computerized Medical Records
  J Med Systems, 2:24l-248, l978.
•   Karnegis JN, Matts J, Tuna N, Amplatz K, Moore RB, Buchwald H
  Directional ST-segment deviation in graded exercise tests correlated with motion of the individual segments of the left ventricular wall. Am J Cardiol. 1983 Sep 1;52(5):449-52.
•   Karnegis JN, Matts J, Tuna N, Amplatz K, Moore RB, Buchwald H
  Quantitative assessment of left ventricular function after myocardial infarction using the minnesota Q-QS codes for resting electrocardiograms. Cathet Cardiovasc Diagn. 1985;11(4):393-400.
•   Karnegis JN, Matts J, Tuna N, Amplatz K
  Comparison of exercise-positive with recovery-positive treadmill graded exercise tests. Am J Cardiol. 1987 Sep 1;60(7):544-7.
•   Karnegis JN, Matts J, Tuna N, Amplatz K
  Relation between Q-QS changes on the rest electrocardiogram and left ventricular function with healed myocardial infarction. Am J Cardiol. 1986 Sep 1;58(6):399-405.
•   Karnegis JN, Matts J, Tuna N
  Development and evolution of electrocardiographic Minnesota Q-QS codes in patients with acute myocardial infarction. Am Heart J. 1985 Aug;110(2):452-9.
•   Karnegis JN, Matts JP, Tuna N, Amplatz K
  Estimation of left ventricular ejection fraction with healed myocardial infarction by multiple regression analysis of electrocardiographic Minnesota Q-QS codes. POSCH Group. J Electrocardiol. 1990 Jan;23(1):1-7.
•   Karnegis JN, Matts JP, Tuna N, Amplatz K
  Positive and negative exercise test results with and without exercise-induced angina in patients with one healed myocardial infarction: analysis of baseline variables and long-term prognosis. Am Heart J. 1991 Sep;122(3 Pt 1):701-8.
•   Karnegis JN, Matts JP, Tuna N, Hunter D, Amplatz K
  Correlation of coronary with peripheral arterial stenosis. The POSCH Group. Atherosclerosis. 1992 Jan;92(1):25-30.
•   Long JM, Brashear JR, Matts JP, Bearman JE
  The POSCH Information Management System: experience with alternative approaches. J Med Syst. 1980;4(3-4):355-66.
•   Long JM, Brashear JR, Matts JP, et al: The Evolution of a Large Clinical Database
  Proceedings of Medcomp, 82:224-229, 1982.
•   Long JM, Slagle JR
  Expert systems, clinical data analyses, and knowledge discovery: the POSCH AI project. Ann N Y Acad Sci. 1992 Dec 17;670:146-54.
•   Long JM
  The POSCH data processing experience. The problem of metadata. J Med Syst. 1986 Apr;10(2):173-83.
•   Long JM: Discovery and Confirmation of Causal Relationships in a Large Medical Record Database: A POSCH Experiment
  Society for Clinical Trials, Annual Conference, 1985.
•   Long JM: The POSCH Secondary Intervention Trial
  Proc Int Cong Prev Cardiology, Moscow, 1985.
•   Long, JM, Brashear JR: Database Management for Clinical Trials
  AFIPS Conference Proceedings: l977 National Computer Conference. AFIPS Press, Montvale, New Jersey, l977, 59-62.
•   Long, JM, Brashear JR: Experience Using Standard Software to Provide a Comprehensive Information Processing System for a Large and Complex Clinical Study
  Proceedings of the Second Annual Symposium on Computer Application in Medical Care. IEEE, New York, New York, l978, 563-565.
•   Matts JP, Buchwald H, Fitch LL, Campos CT, Varco RL, Campbell GS, Pearce MB, Yellin AE, Edmiston WA, Smink RD Jr, et al
  Program on the Surgical Control of the Hyperlipidemias (POSCH): patient entry characteristics. The POSCH Group. Control Clin Trials. 1991 Apr;12(2):314-39.
•   Matts JP, Buchwald H, Fitch LL, Campos CT, Varco RL, Campbell GS, Pearce MB, Yellin AE, Smink RD Jr, Sawin HS Jr, et al
  Subgroup analyses of the major clinical endpoints in the Program on the Surgical Control of the Hyperlipidemias (POSCH): overall mortality, atherosclerotic coronary heart disease (ACHD) mortality, and ACHD mortality or myocardial infarction. J Clin Epidemiol. 1995 Mar;48(3):389-405.
•   Matts JP, Karnegis JN, Campos CT, Fitch LL, Johnson JW, Buchwald H
  Serum creatinine as an independent predictor of coronary heart disease mortality in normotensive survivors of myocardial infarction. POSCH Group. J Fam Pract. 1993 May;36(5):497-503.
•   Matts JP, McHugh RB
  Analysis of accrual randomized clinical trials with balanced groups in strata. J Chronic Dis. 1978;31(12):725-40.
•   Moore RB, Buchwald H, Varco RL
  The effect of partial ileal bypass on plasma lipoproteins. Circulation. 1980 Sep;62(3):469-76.
•   Moore RB, Long JM, Matts JP, Amplatz K, Varco RL, Buchwald H
  Plasma lipoproteins and coronary arteriography in subjects in the program on the surgical control of the hyperlipidemias. Preliminary report. Atherosclerosis. 1979 Feb;32(2):101-19.
•   Obialo CI, Clayman RV, Matts JP, Fitch LL, Buchwald H, Gillis M, Hruska KA
  Pathogenesis of nephrolithiasis post-partial ileal bypass surgery: case-control study. The POSCH Group. Kidney Int. 1991 Jun;39(6):1249-54.

Details for clinical trial NCT00000490